Market Research Report
Sudden Sensorineural hearing loss (SSNHL) - Market Insights, Epidemiology, and Market Forecast - 2028
|Published by||DelveInsight Business Research LLP||Product code||915410|
|Published||Content info||159 Pages
Delivery time: 1-2 business days
|Sudden Sensorineural hearing loss (SSNHL) - Market Insights, Epidemiology, and Market Forecast - 2028|
|Published: November 1, 2019||Content info: 159 Pages||
DelveInsight's 'Sudden Sensorineural hearing loss (SSNHL)-Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Sudden Sensorineural hearing loss in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Sudden Sensorineural hearing loss from 2017 to 2028 segmented by seven major markets.
Sudden Sensorineural hearing loss (SNHL) is the most common type of hearing loss, referred colloquially as "nerve hearing loss", which indicates abnormal functioning of the cochlea, auditory nerve, or higher aspects of central auditory perception or processing. Sudden Sensorineural hearing loss (SSNHL) is a subset of SHL that is sensorineural in nature, occurs within a 72-h window, and meets certain audiometric criteria. In major parts of the world, Sudden Sensorineural hearing loss (SSNHL) is most often defined as "Sensorineural hearing loss of 30 dB or greater over at least three contiguous audiometric frequencies occurring over 72 h". In 2012, The Research Committee of the Ministry of Health and Welfare for Acute Profound Deafness in Japan also accepted this definition.
Study Period: 2017-2028
Sudden Sensorineural hearing loss - Disease Understanding and Diagnosis
SSNHL can be categorized into congenital and acquired sensorineural hearing loss. Congenital sensorineural hearing loss happens during pregnancy, some causes include prematurity, maternal diabetes, lack of oxygen during birth, genetics, and others. Whereas acquired sensorineural hearing loss occurs after birth and is speculative and probably multifactorial, but various etiological theories have been proposed. Infection, vascular impairment, autoimmune disorders, trauma, inner ear anomaly, central nervous system (CNS) disease have all been implicated, but in many patients, no obvious cause is found (idiopathic). Cardiovascular disease, cigarette smoking, and hypertension appear to be the most common risk factors associated with SSNHL. Advanced age, severe hearing loss, heredity, audiogram shape, and presence of vertigo are significant negative prognostic indicators for untreated SSNHL.
For the diagnosis of the SSNHL, it is important to distinguish between conductive hearing loss and sensorineural hearing loss. The diagnosis of congenital hearing loss starts with a newborn hearing screening. A thorough history and a careful physical examination are essential to the diagnosis and treatment of hearing loss. Weber's test is performed by softly striking a 512-Hz tuning fork and placing it midline on the patient's scalp, or on the forehead, nasal bones, or teeth. If the hearing loss is conductive, the sound will be heard best in the affected ear. If the loss is sensorineural, the sound will be heard best in the normal ear. The sound remains midline in patients with normal hearing.
The Sudden Sensorineural hearing loss epidemiology division provides insights about historical and current incident pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident cases of SSNHL, Gender-Specific cases of SSNHL, Age-Specific cases of SSNHL, Severity Specific cases of SSNHL, and Nature Specific cases of SSNHL) scenario of Sudden Sensorineural Hearing loss in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.
According to DelveInsight, the total Incident cases of Sudden Sensorineural hearing loss (SSNHL) in the 7MM was found to be 331,961 in 2017. The incidence of Sudden Sensorineural hearing loss in the 7MM is expected to increase during the study period of 2017-2028.
This segment of the Sudden Sensorineural hearing loss report encloses the detailed analysis of late-stage (Phase-III and Phase-II) pipeline drugs and other potential drug candidates. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Sudden Sensorineural hearing loss (SNHL) is commonly encountered in audiology and otolaryngologic practice. Several agents have been explored for the treatment of idiopathic SNHL, including corticosteroids, anti-inflammatory agents, antimicrobials, calcium antagonists, vitamins, essential minerals, vasodilators, volume expanders, defibrinogenators, diuretics, and hyperbaric oxygen. SNHL may be managed with hearing aids, when hearing aids are not enough, this type of hearing loss can be surgically treated with cochlear implants.
Detailed chapters of emerging therapies, such as Sonsuvi (AM-111) (Auris Medical), STR001 (Strekin AG), SENS-401 (Sensorion), FX-322 (Frequency Therapeutics), and also details about some potential therapies such as Valganciclovir (Genentech), LY3056480 (Audion Therapeutics), and Anakinra (Swedish Orphan Biovitrum), others have also been provided in the report.
The Sudden Sensorineural hearing loss market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
According to DelveInsight, the market for Sudden Sensorineural hearing loss in 7MM was found to be approximately USD 110.91 Million in 2017.
Sudden Sensorineural hearing loss market size in EU-5 accounted for 45% of the total market in 2017. The EU-5 led the market in 2017, followed by the United States and Japan, respectively. Due to the high incidence of this disease in the region, the Sudden Sensorineural hearing loss treatment market in the EU-5 is expected to dominate the market during the forecast period (2019-2028).
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.
The dynamics of Sudden Sensorineural hearing loss market is anticipated to change in the coming years owing to the expected launch of emerging therapies, such as Sonsuvi (AM-111) (Auris Medical), STR001 (Strekin AG), SENS-401 (Sensorion), FX-322 (Frequency Therapeutics), and others in the Sudden Sensorineural hearing loss market by 2028.